Clinical trials: Patients With Suspected Prostate Cancer
Prostate Cancer
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
- Trial name
- NCT03809078
- Testing
- 68Ga RM2, 68Ga-PSMA-11, Investigational PET scanner coils and software
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Andrei Iagaru
Health Status Unknown, Prostate Carcinoma
Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer
This pilot clinical trial studies transrectal magnetic resonance imaging (MRI)-guided biopsy to see how well it works in identifying cancer in patients with suspected prostate cancer who are scheduled to undergo standard biopsy.
- Trial name
- NCT02501759
- Testing
- 3 Tesla Magnetic Resonance Imaging, Gadodiamide, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer, Prostate Neoplasm
Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient
The diagnostic tools for detecting patients with early prostate cancer are limited due to poor diagnostic performance. The positron emission tomography (PET) combination with the diagnostic radiopharmacy is a non-invasive tool to…
- Trial name
- NCT05422105
- Testing
- 18F-PSMA-1007
- Where
- 2 sites in Taiwan
- Volunteers
- 230 people
- Sponsor
- Primo Biotechnology Co., Ltd
Oncology, Prostate Cancer
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
A [18]F-PSMA-1007 PET/CT or PET/MRI scan are nuclear medicine tests used to create pictures of the whole body that may show where cells that express Prostate-Specific Membrane Antigen (PSMA) are found.
- Trial name
- NCT05712174
- Testing
- [18]F-PSMA-1007
- Where
- Canada
- Volunteers
- 176 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer
PET/MRI in Patients With Suspected Prostate Cancer
This diagnostic clinical trial will be conducted according to a randomized, prospective, controlled, double-arm, single-centre design.
- Trial name
- NCT02659527
- Testing
- 68Ga- PSMA-HBED-CC, Biograph mMR, Siemens
- Where
- Austria
- Volunteers
- 220 people
- Sponsor
- Medical University of Vienna
Prostate Cancer
64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer
This research project is testing a new compound which may potentially detect specific cancer lesions in men with prostate cancer.
- Trial name
- NCT05286840
- Testing
- 64Cu-SAR-bisPSMA
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Luke Nordquist, MD
Healthy Male Subjects, Suspected Prostate Cancer
A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer
Phase I/II study in the management of Healthy Male Subjects and patients with suspected prostate cancer.
- Trial name
- NCT06472531
- Testing
- INR101
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd
Patients With Suspected Prostate Cancer
Multicentric Comparative Prospective Study of the Benefits and Risks of Biopsy Prostate Using Transrectal or Transperineal Procedure for the Prostate Cancer Diagnostic
The performance of prostatic biopsies is an essential element to confirm the diagnosis of prostate cancer and to specify the characteristics of the tumor in terms of stage and grade.
- Trial name
- BIOPROSTABORD (NCT05763355)
- Testing
- Biopsy
- Where
- 2 sites in France
- Volunteers
- 101 people
- Sponsor
- Elsan
Prostate Cancer
The Value of Dual-parametric Magnetic Resonance Combined With Regional Saturation Biopsy in Patients With Suspected Prostate Cancer
The aim of this study was to investigate the value of dual-parameter magnetic resonance imaging(bpMRI) combined with regional saturation biopsy in the diagnosis of prostate cancer by means of a prospective randomized controlled…
- Trial name
- NCT06824259
- Testing
- Follow up if MRI is negative, Systematic biopsy if MRI is negative
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking University First Hospital
Prostate Cancer
Conducting Active Surveillance Without Prostate Biopsy for Patients With Low-risk Suspected Prostate Cancer
The goal of this observational study is to evaluate the role of the USTC diagnostic model in risk-adaptive strategies for biopsy decision-making in patients with low-risk suspected prostate cancer in order to reduce unnecessary…
- Trial name
- ASWBP (NCT05940415)
- Testing
- active surveillance
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Anhui Provincial Hospital
Patients With Suspected Prostate Cancer
Analysis of a New Biomarker for Prostate Cancer Diagnosis
The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.
- Trial name
- HEM (NCT01819740)
- Testing
- determine the levels of the "HEM" substance in seminal plasma
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Corporacion Parc Tauli
Prostate Cancer
3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer
In standard clinical care, the prostate is imaged by magnetic resonance imaging (MRI) which is a procedure to take pictures of body structures by using a strong magnetic field and radio waves.
- Trial name
- NCT01653093
- Testing
- 3-Tesla magnetic resonance imaging (3T MRI), diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- University of Cincinnati
Prostate Cancer
SonoVue Guided Prostate Biopsy
This is a phase III European multicenter, open label, prospective study to assess the diagnostic accuracy of the use of SonoVue contrast agent to guide prostate biopsies in comparison with the current practice of ultrasound…
- Trial name
- NCT00911027
- Testing
- Contrast-enhanced ultrasound guided biopsy, ultrasound guided systematic biopsy
- Where
- 17 sites in Austria, Belgium and 5 more
- Volunteers
- 282 people
- Sponsor
- Bracco Diagnostics, Inc
Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph…
- Conditions
- Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT01409200
- Testing
- Antiandrogen Therapy, Axitinib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
This study evaluates the diagnostic performance and safety of 68Ga-NYM032 PET/CT imaging in patients with suspected recurrence of prostate cancer.
- Trial name
- NCT07649122
- Testing
- 68-Ga-NYM032
- Where
- 2 sites in China
- Volunteers
- 232 people
- Sponsor
- Norroy Bioscience Co., LTD
High Risk Prostate Carcinoma
[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
This is a multi-center, open-label, single arm Phase III clinical trial for the diagnostic efficacy assessment and safety evaluation by [18F]Florastamin PET/CT imaging examination to determine the presence of recurrent or…
- Trial name
- NCT05936658
- Testing
- [F-18]Florastamin
- Where
- 6 sites in South Korea
- Volunteers
- 138 people
- Sponsor
- FutureChem
Prostate Cancer
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
In this study, 18F-Florastamin PET/CT will be performed in patients with suspected recurrence of prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
- Trial name
- NCT06754085
- Testing
- Florastamin[18F] Injection
- Where
- China
- Volunteers
- 131 people
- Sponsor
- HTA Co., Ltd.
Prostate Cancer With PSA Gray Zone
Intelligent Screening and Precision Diagnosis of Prostate Cancer Based on Multimodal Data
This project aims to develop a precision screening and diagnostic solution for prostate cancer based on multimodal artificial intelligence, focusing on addressing the diagnostic challenge in patients within the PSA "gray zone" of…
- Trial name
- NCT07631806
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Prostate Cancer (Adenocarcinoma)
Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations
The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time.
- Trial name
- NCT06655064
- Testing
- None- Observational
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited